Medicus Pharma Ltd. Common Stock

Medicus Chief Medical Officer will Highlight Company's Focus on Precision Oncology, Anchored by CD228V targeted ADC and Partner Ready Therapeutic Programs Medicus Chief Medical Officer will Highlight Company's Focus on Precision Oncology, Anchored by CD228V targeted ADC and Partner Ready Therapeutic Programs

PHILADELPHIA, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a precision guided, biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets, today announced that it will host a financial performance and business update conference call on Monday, November 9, 2026, at 11:30 a.m.

PHILADELPHIA, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”), a precision guided, biotech/life sciences company focused on advancing novel and potentially disruptive therapeutic assets, today announced that, its wholly-owned subsidiary, Skinject, Inc. (“SkinJect”), has entered into a non-binding letter of intent ("LOI") with an undisclosed special purpose acquisition company ("SPAC") for a proposed business combination involving SkinJect (“Busin…

Company's Executive Chairman and CEO to Speak on Cancer Therapeutics Spotlight Panel at BioFuture in NYC and Deliver Keynote Address at Global Biotechnology Summit in Abu Dhabi Company's Executive Chairman and CEO to Speak on Cancer Therapeutics Spotlight Panel at BioFuture in NYC and Deliver Keynote Address at Global Biotechnology Summit in Abu Dhabi

Nasdaq closes the minimum bid price matter confirming that the Company has regained compliance Nasdaq closes the minimum bid price matter confirming that the Company has regained compliance

Medicus Pharma (NASDAQ:MDCX) is positioning its precision oncology-led pipeline for a series of clinical and regulatory milestones, with partnerships and licensing deals central to the next phase of development, the company said in a shareholder update marking its third anniversary.  The Nasdaq-listed biotech said its priorities are to advance selected clinical and regulatory milestones, align organizational costs with those priorities, and pursue licensing and co-development opportunities.

PHILADELPHIA, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”), a precision guided, biotech/life sciences company focused on advancing novel and potentially disruptive therapeutic assets, today provided a shareholder update celebrating its third anniversary, highlighting three years of progress, focused on execution and capital efficient drug development.

Medicus Pharma (NASDAQ:MDCX) has submitted a seamless Phase 2b/3 registration-intent protocol to the US Food and Drug Administration for Teverelix, its long-acting GnRH antagonist for advanced prostate cancer patients at increased cardiovascular risk.  The company said the stage-gated design starts with about 80 randomized patients, replacing a previously FDA-cleared, stand-alone 40-patient open-label dose-optimization study.

Proposed seamless design would incorporate previously FDA-cleared dose-optimization work into a single registration-intent program aligning it with Company's capital-efficient development strategy Proposed seamless design would incorporate previously FDA-cleared dose-optimization work into a single registration-intent program aligning it with Company's capital-efficient development strategy

Medicus Pharma (NASDAQ:MDCX) said it will focus future internally sponsored clinical development of SkinJect exclusively on Gorlin syndrome patients with multiple basal cell carcinoma lesions and will conclude further development in sporadic/nodular basal cell carcinoma. The decision builds on the company's portfolio strategy announced earlier this month, under which Medicus is concentrating resources on programs offering the most compelling risk-adjusted opportunity.

PHILADELPHIA, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd.

Medicus Pharma (NASDAQ:MDCX) earlier this week outlined progress across its SkinJect program and a co-development and licensing opportunity with Pfizer, with CEO Raza Bokhari highlighting clinical, partnership and funding developments as the company sharpens its focus on precision oncology and capital-efficient drug development. Bokhari said final SkinJect results published on ClinicalTrials.gov had confirmed the 200-microgram patch as the dose to be taken forward into further registrational stu…

Positive tone Wall Street opened sharply higher on Friday, with the Dow Jones Industrial Average and S&P 500 both gaining 1.1% and the Nasdaq rising 1.2% as...

Medicus Pharma (NASDAQ:MDCX) said a completed Phase 2 study of its SkinJect therapy showed all 90 enrolled patients finished treatment without discontinuations, data the company says will guide its next-stage registrational trial in a rare genetic skin cancer syndrome. The randomized, double-blind, multicenter trial enrolled patients across 10 US investigative sites, comparing two dose levels of SkinJect against a device-only microneedle comparator.

CSR provides a clinical foundation for the Company's recently announced capital-efficient focus on FDA-authorized Gorlin Syndrome NDA-enabling development program while supporting partnership discussions to advance nodular Basal Cell Carcinoma CSR provides a clinical foundation for the Company's recently announced capital-efficient focus on FDA-authorized Gorlin Syndrome NDA-enabling development program while supporting partnership discussions to advance nodular Basal Cell Carcinoma

10:05am: Rising yields pressure stocks Stocks moved lower at the open on Thursday as Treasury yields climbed to their highest level in years and oil prices...

4:20pm: Treasury yields climb Wall Street extended its selloff on Wednesday, with the Dow Jones Industrial Average falling 440 points as oil prices topped...

Medicus Pharma (NASDAQ:MDCX) is repositioning itself as a precision oncology-led biotechnology company, centering its strategy on CD228V, a second-generation antibody-drug conjugate targeting CD228-expressing solid tumors, the company said Tuesday. CD228V is now the company's principal strategic priority, with initial development focused on establishing clinical proof-of-concept in a selected tumor population.

Company prioritizes CD228V precision oncology development in Melanoma while pursuing capital-efficient partnerships for SkinJect® and Teverelix® indications Company prioritizes CD228V precision oncology development in Melanoma while pursuing capital-efficient partnerships for SkinJect® and Teverelix® indications

Medicus Pharma Ltd. (NASDAQ:MDCX) secured on Wednesday an exclusive, sublicensable global license from Pfizer Inc. (NYSE:PFE) to develop, manufacture, and commercialize PF-08046031 (CD228V), an early clinical-stage antibody-drug conjugate targeting melanotransferrin.